Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2009 Aug 27.
Published in final edited form as: Chemistry. 2008;14(23):7072–7081. doi: 10.1002/chem.200800757

Pre-activation Based One-pot Synthesis of an α-(2,3)-Sialylated Core-Fucosylated Complex Type Bi-antennary N-Glycan Dodecasaccharide

Bin Sun a,b, Balasubramanian Srinivasan a, Xuefei Huang a,b,
PMCID: PMC2733368  NIHMSID: NIHMS110814  PMID: 18601234

Abstract

Synthesis of N-glycans is of high current interests due to their important biological properties. A highly efficient convergent strategy based on the pre-activation method for assembly of the complex type core fucosylated bi-antennary N-glycan dodecasaccharide has been developed. Retrosynthetically, this extremely challenging target is broken down to three modules: a sialyl disaccharide, a glucosamine building block and a hexasaccharide diol acceptor. The sialyl disaccharide was easily obtained by selective activation of a new 5-N-trichloroacetyl protected sialyl donor in the presence of a thiogalactoside acceptor. The hexasaccharide diol module was produced by double mannosylation of a fucosylated tetrasaccharide acceptor, which in turn was generated by glycosylation of a α-fucosylated disaccharide with a β-mannose containing disaccharide donor. The union of the three modules was performed in one pot giving the fully protected dodecasaccharide in high yield. This synthesis is characterized by minimum protective group and aglycon adjustment on oligosaccharide intermediates, thus greatly enhancing the overall synthetic efficiency. The modular feature of this strategy suggests that this method can be readily adapted to the synthesis of a wide variety of N-glycan structures.

Introduction

Glycosylation is one of the major types of postsynthetic modification of mammalian proteins, which include the attachment of oligosaccharides to asparagine (N-glycan) and to serine or threorine (O-glycan).[1] Unlike protein synthesis, the addition of carbohydrates to proteins is not under direct genetic control, which often leads to heterogeneous glycosylation patterns on the same protein backbone. The identities of carbohydrate moieties can have a profound effect on biological functions of glycoproteins such as their immunogenecities, stabilities, and affinities to receptors.[14] However, despite intensive studies, detailed structure-function relationships have not been established in many cases, mainly due to the difficulties in accessing sufficient quantities of these glycan structures.

We became interested in the synthesis of α-(2,3)-sialylated core-fucosylated complex type bi-antennary N-Glycan dodecasaccharide 1, which is one of the prototypical structures of mammalian N-glycans.[5] The dodecasaccharide 1 has been found on alpha fetoprotein (AFP) isolated from patients having hepatocellular carcinoma, a form of liver cancer. It is proposed that the structures of N-glycans can be a much more reliable marker to differentiate benign and malignant liver diseases.[6, 7] Similarly, studies on N-glycans linked to prostate specific antigen (PSA) suggest that α-(2,3) linked sialylated N-glycan on PSA can be potentially used to identify prostate cancer.[8] Dodecasaccharide 1 has also been found on the surface of erythropoietin.[9] The presence of fucose and sialic acid moieties in attached carbohydrates is believed to be important for the in vivo activity of erythropoietin.[10] There are intense interests in remodeling glycoproteins such as erythropoietin with homogeneous carbohydrate structures.[11] Thus, the ready availability of dodecasaccharide 1 can greatly facilitate the exploration of its glyco-biological functions and biomedical applications.

Although N-glycan structures can be assembled via several approaches,[1223] total synthesis of dodecasaccharide 1 via chemical methods still presents a daunting task, which requires the construction of many difficult glycosyl linkages such as β-mannose, α-sialic acid, α-fucose as well as branching sequences. Moreover, the acid lability of the fucosyl linkage limits the scope of reagents that can be used. To date the only chemical total synthesis of the dodesaccharide in its fully protected form was accomplished by the Danishefsky group using a variety of glycosyl donors including glycals, thioglycosides, glycosyl sulfoxide, glycosyl fluoride and glycosyl phosphite. The tour-de-force total synthesis took 20 steps starting from protected monosaccharide building blocks with 13 steps and 3.1% overall yield for the longest linear sequence.[11, 24] Herein, we report our studies on an efficient chemical synthesis of dodecasaccharide 1 via the pre-activation based one pot method predominantly using p-tolyl thioglycosides to simplify building block design.

Results and Discussion

In order to enhance the overall efficiency, our synthetic sequence was designed to minimize protective group manipulations and aglycon adjustments on intermediate oligosaccharides while achieving high stereoselectivities and yields. Previously, we discovered that the reaction of a mannosyl diol acceptor with a thiomannosyl donor in the absence of a participating protective group on its 2-O position led to products as an anomeric mixture.[26] Therefore, the strategic disconnections between glycan rings C/D and C’/D’ in dodecasaccharide 2 were chosen, leading to ABC trisaccharide fragment 3 and the core DD’EFGH hexasaccharide 4 (Scheme 1).

Scheme 1.

Scheme 1

Retrosynthetic analysis of dodecasaccharide 1.

For the installation of DD’ units in 4, to minimize the steric hindrance to the 3-O position of the E mannosyl unit, a popular strategy is to introduce the D’ unit first followed by protective group adjustment and glycosylation on the 6-O position.[12, 27] For higher efficiency, we decided to explore the possibility of double mannosylation[17, 28] of tetrasaccharide 6 by the 2-O acetylated thiomannoside 5. In tetrasaccharide 6, the formation of β-mannosyl linkage between ring E and F is crucial. β-Mannosides can be accessed via a variety of methods, including SN2 inversion of β glucosides[15, 18, 29] intramolecular aglycon delivery,[27, 30, 31] insoluble silver salt promoted mannosyl halide reaction[32] and glycosylation by benzylidene bearing mannosyl donors.[3335] The ground breaking work by Crich and coworkers has demonstrated high β selectivity can be obtained using benzylidene bearing mannosyl donors,[3336] although the aglycon of the product typically needs to be further modified to convert it into a suitable donor for subsequent glycosylation to extend the chain.[20]

Our journey commenced from the preparation of the reducing end disaccharide 9 through fucosylation of diol acceptor 8[37] by donor 7 (Scheme 2a).[38] Although exclusive α selectivity was obtained when donor 7 reacted with acceptors containing secondary hydroxyl groups using N-iodosuccinimide/triflic acid or p-TolSCl/AgOTf promoter systems,[3941] α:β mixtures were generated with acceptors bearing primary hydroxyl groups under these conditions. In order to enhance the α selectivity, we applied the in situ anomerization protocol (CuBr2, tetrabutylammonium bromide)[27, 28, 42] first developed by Lemieux and coworkers.[43] Satisfactory yield (75 %) was obtained for the desired disaccharide 9, with its regio- and stereo-chemistry confirmed by NMR analysis.

Scheme 2.

Scheme 2

The formation of the key β mannosyl linkage using the benzylidene bearing thiomannosyl donor 10 was examined next. Activation of thiomannosyl donor 10α in the absence of any acceptor (pre-activation)[44] by p-TolSOTf, formed in situ through the reaction of p-TolSCl and AgOTf,[44, 45] was followed by addition of thioglycosyl acceptor 11,[46] which formed disaccharide 12 in 57% yield (82% based on the amount of donor consumed) with an β:α ratio of 6:1 (Scheme 2b). The aglycon stereochemistry of the donor did not affect the reaction as donor 10β gave identical result as 10α. The newly formed glycosyl linkage in 12β was confirmed by the one bond coupling constant between the anomeric carbon and proton of the mannose moiety (1J (C1,H1) = 157 Hz).[47] Disaccharide 12β was then directly used as a donor without any aglycon manipulations.

The reaction of disaccharide 12β and 9 promoted by p-TolSCl/AgOTf produced the desired tetrasaccharide 13 despite the presence of the bulky fucosyl group on the 6-O position of acceptor 9. However, treatment of 13 with PhBCl2 and Et3SiH for opening the benzylidene group[48] cleaved off the fucose unit. After several alternative reaction routes including postponing the introduction of fucose were explored, the most efficient way was determined to be adjusting the protective groups on disaccharide 12β. The p-methoxybenzyl (PMB) group in 12β can be oxidatively removed first followed by benzylidene opening.[19, 49] We discovered that mixing PhBCl2 and Et3SiH with 12β not only regioselectively converted the benzylidene group to 4-O benzyl but also removed the 3-O-PMB group simultaneously, leading to a diol which was subsequently protected as levulinoyl ester 14 (Scheme 2c, 77%). Reaction of the levulinoyl disaccharide donor 14 with fucosylated acceptor 9 proceeded smoothly in 86% yield. The two Lev moieties in the tetrasaccharide product 15 were selectively deprotected using hydrazine acetate giving diol 6 (Scheme 2c). Double mannosylation of 6 by donor 5 was explored next with our p-TolSCl/AgOTf promoter. A product with the same molecular weight as the desired hexasaccharide was isolated, which was found to be extremely labile to acid. NMR studies suggested that it was an orthoester. To overcome this problem, TMSOTf[50] was added at the end of the glycosylation reaction at 0 °C to rearrange the orthoester in situ. Gratifyingly, the desired hexasaccharide 16 was obtained in 77% yield following TMSOTf promoted rearrangement (Scheme 2d). Hexasaccharide 16 was then de-acetylated resulting in the core hexasaccharide diol acceptor 4.

Next we focused our attention on the assembly of the branching sequence. Sialylation is known to be notoriously difficult due to the low reactivity of the sialyl donor and the challenge in stereochemical control.[51] The presence of the carboxylic acid moiety in sialic acid also necessitates additional consideration of protective group compatibility in synthetic design.[22] Recently, it was discovered that the replacement of the 5-N-acetyl group on a sialyl donor with an electron withdrawing protective group[5261] significantly enhanced the reaction yield and stereoselectivity. Thus, we designed sialyl donor 17 bearing the 5-N trichloroacetyl (TCA) moiety, as NH-TCA can be converted to acetamide under a variety of reaction conditions including hydrogenolysis, radical reduction and basic cleavage followed by acetylation.[6264] The trifluoroacetimidate aglycon leaving group[58, 65, 66] was chosen due to the possibility for its selective activation over a thioglycoside. This was realized by treating a mixture of donor 17 and thiogalactoside acceptor 18[6264] with a catalytic amount of TMSOTf leading to disaccharide 24 in 68% yield (Table 1, entry 1), which was benzoylated to give disaccharide 30. The α sialyl linkage was confirmed by the three bond coupling constant between C1 and H3ax (3J (C1,H3ax) = 5.8 Hz) of the sialic acid.[67] The scope of this sialylation reaction was examined next. A variety of acceptors including primary alkyl alcohol, carbohydrate hydroxyl groups of galactose, galactosamine and glucosamine were sialylated in good yields and stereoselectivities, which represented some of the common natural sialyl linkages (Table 1). Acid labile benzylidene and isopropylidene groups were stable under the reaction condition. In addition to acceptor 18, thioglycoside 23 also served as an excellent substrate for the reaction. This selective activation protocol is attractive as the resulting sialylated thioglycoside product can be used as a donor for further glycosylation without additional aglycon leaving group adjustment.

Table 1.

Sialylation Results using Sialyl Donor 17

graphic file with name nihms110814t1.jpg
Entry Acceptor Product Yield (α : β)a)
1 graphic file with name nihms110814t2.jpg graphic file with name nihms110814t3.jpg 68% (α only)
2 graphic file with name nihms110814t4.jpg graphic file with name nihms110814t5.jpg 75 % (14:1)
3 graphic file with name nihms110814t6.jpg graphic file with name nihms110814t7.jpg 91 % (33:1)
4 graphic file with name nihms110814t8.jpg graphic file with name nihms110814t9.jpg 85 % (13:1)
5 graphic file with name nihms110814t10.jpg graphic file with name nihms110814t11.jpg 85% (α only)
6 graphic file with name nihms110814t12.jpg graphic file with name nihms110814t13.jpg 77% (α only)
[a]

Anomeric ratios were determined by 1 H NMR analysis

With all building blocks in hand, one pot glycosylation was performed using the pre-activation based protocol (Scheme 3).[39, 44, 46, 68, 69] Pre-activation of disaccharide 30 by p-TolSCl/AgOTf,[44, 45] was rapidly achieved at −78 °C. Addition of the thioglycosyl acceptor 31[39] to the reaction mixture produced trisaccharide 3,[38] which underwent double glycosylation of hexasaccharide 4 in the same reaction flask leading to dodecasaccharide 2. It took only four hours for this three-component one pot assembly process and the desired dodecasaccharide 2 was easily isolated from the reaction by flash column chromatography in an excellent 65% yield from disaccharide 30.

Scheme 3.

Scheme 3

Deprotection in complex oligosaccharide synthesis can be very challenging. Previously, Ito and coworkers reported that the removal of dichlorophthalimide (DCPhth) group in the presence of protected sialic acids did not lead to the desired product presumably due to cross reactivities of the methyl ester of sialic acids with reagents used to remove DCPhth and vice versa.[22] They designed an elegant approach by first converting all DCPhth groups into azide prior to the attachment of sialic acid, thus bypassing the cross reactivity problem. As an alternative, we explored the possibility of deprotecting sialic esters in the presence of phthalimide (Phth) groups. Treatment of the fully protected dodecasaccharide 2 with LiI in pyridine[54, 70] at 110 °C cleanly cleaved the two methyl esters without affecting the Phth groups (Scheme 4). The resulting dicarboxylic acid was then added to hydrazine in refluxing ethanol, which was followed by selective acetylation in methanol to yield compound 32. The usage of ethylene diamine instead of hydrazine to remove the Phth groups led to a lower yield. Finally, the fully deprotected dodecasaccharide 1 was produced by catalytic hydrogenolysis of 32 with Pd(OH)2/C (49% overall yield from 2). The NMR and MS data of 1 are consistent with its structure.

Scheme 4.

Scheme 4

Conclusion

We have achieved a stereocontrolled synthesis of the fucosylated complex type N glycan dodecasaccharide 2 via the pre-activation based chemoselective glycosylation method. This is the most complex oligosaccharide assembled by any one pot methods to date, which contains twelve monosaccharide units and several synthetically challenging linkages such as α-sialic acids, β-mannose, α-fucose as well as branching. Starting from monosaccharide building blocks, dodecasaccharide 2 was produced in a total of 10 steps with 7 steps and 11% overall yield for the longest linear sequence. The successful completion and high efficiency of this synthesis highlight the power of the pre-activation based approach. Due to the convergent modular approach taken, this strategy can be readily adapted towards the assembly of a library of N glycan sequences including bisecting GlcNAc and multi-antennary structures as well as un-natural N glycan analogs. We are currently synthesizing other N-glycan sequences and investigating the usage of these molecules as disease markers for early diagnosis.

Experimental Section

General Experimental Procedures

All reactions were carried out under nitrogen with anhydrous solvents in flame-dried glassware, unless otherwise noted. All glycosylation reactions were performed in the presence of molecular sieves, which were flame-dried right before the reaction under high vacuum. Glycosylation solvents were dried using a solvent purification system and used directly without further drying. Chemicals used were reagent grade as supplied except where noted. Analytical thin-layer chromatography was performed using silica gel 60 F254 glass plates; Compound spots were visualized by UV light (254 nm) and by staining with a yellow solution containing Ce(NH4)2(NO3)6 (0.5 g) and (NH4)6Mo7O24 4H2O (24.0 g) in 6% H2SO4 (500 mL). Flash column chromatography was performed on silica gel 60 (230–400 Mesh). NMR spectra were referenced using Me4Si (0 ppm), residual CHCl3 (δ 1H-NMR 7.26 ppm, 13C-NMR 77.0 ppm). Peak and coupling constant assignments are based on 1H-NMR, 1H-1H gCOSY and (or) 1H-13C gHMQC and 1H-13C gHMBC experiments. All optical rotations were measured using the sodium D line. ESI mass spectra were recorded using ESQUIRE Ion Trap LC/MS. High-resolution mass spectra were recorded on a Micromass electrospray mass spectrometer equipped with an orthogonal electrospray source (Z-spray) operated in positive ion mode.

Characterization of anomeric stereochemistry

The stereochemistries of the newly formed glycosidic linkages in oligosaccharides (except sialyl and mannosyl linkages) are determined by 3J (H1, H2) through 1H-NMR and/or 1J (C1, H1) through gHMQC 2-D NMR (without 1H decoupling). Smaller coupling constants of 3JH1.H2 (around 3 Hz) indicate 1,2-cis α linkages and larger coupling constants 3J (H1,H2) (7.2 Hz or larger) indicate 1,2-trans β linkages. This can be further confirmed by 1JC1,H1 (∼170 Hz) for α linkages and 1J (C1,H1) (∼160 Hz) for β linkages.[47] For the mannosyl linkages, one bond coupling constants between C1 and H1 were measured by gHMQC 2-D NMR. 1J (C1, H1) ∼170 Hz indicates α-mannosyl linkages and 1J (C1, H1) ∼160 Hz suggests β linkages. For the sialyl linkages, three bond coupling constants between C1 and H3ax of the sialic acid was measured by gHMBC 2-D NMR. 1J (C1, H3ax) ∼ 5.8 Hz indicates α-sialyl linkage and 1J (C1, H3ax) ∼ 1Hz suggests β linkage.

Benzyl 2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1→6)-3-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (9)

A mixture of CuBr2 (0.9 g, 6.27 mmol), Bu4NBr (1.31 g, 4.06 mmol), and molecular sieves 4A (1.2 g) in CH2Cl2/DMF (2:1, 18 mL) was stirred and cooled over an ice-water bath. A solution of compound 7 (1.07 g, 1.98 mmol) and 8 (0.9 g, 1.84 mmol) in CH2Cl2 (12 mL) was added dropwise and the mixture was stirred for 17 h from 0°C to room temperature. The resulting mixture was quenched with aq. NaHCO3, diluted with EtOAc, and filtered through Celite. The filtrate was washed successively with aq. NaHCO3 and brine, and dried over Na2SO4. The organic layer was then evaporated in vacuo. The residue was purified by flush column chromatography (hexanes: EtOAc = 2:1) to afford 9 (1.25 g, 75%). [α]D20 = −78.1, (c = 1.0 in CHCl3). 1H NMR (600 Hz, CDCl3): δ = 7.79 (bs, 1 H), 7.67 (bs, 2 H), 7.52 (bs, 1 H), 7.42-7.40 (m, 2 H), 7.38-7.22 (m, 14 H), 7.08-6.98 (m, 6 H), 6.89-6.86 (m, 3 H), 5.12-5.08 (m, 1 H), 4.98 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.87 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.84 (d, 3J (H, H)= 12 Hz, 1 H), 4.81 (d, 3J(H, H) = 3.6 Hz, 1 H), 4.78 (d, 3J = 12 Hz, 1 H), 4.74-4.70 (m, 2 H), 4.68 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.65 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.46 (d, 3J (H, H) = 12 Hz, 1 H), 4.41 (d, 3J (H, H) = 12.6 Hz, 1 H), 4.16-4.14 (m, 2 H), 4.08-4.06 (dd, 3J (H, H) = 3.6, 10.2 Hz, 1 H), 4.00-3.97 (m, 2 H), 3.94-3.90 (m, 2 H), 3.88-3.84 (dd, 3J (H, H) = 4.2, 10.8 Hz, 1 H), 3.70-3.67 (m, 2 H), 3.57-3.53 (m, 1 H), 1.12 (d, 3J ()H, H = 6.6 Hz, 3 H). 13C NMR (150 Hz, CDCl3): δ = 138.80, 138.79, 138.7, 138.3, 137.3, 133.8, 131.9, 128.72, 128.66, 128.6, 128.52, 128.47, 128.34, 128.25, 128.24, 128.18, 128.1, 127.9, 127.83, 127.76, 127.5, 123.3, 98.9 (C1 fucose, 1J (C1, H1) = 172 Hz), 97.6 (C1 glucosamine, 1J (C1, H1) = 161 Hz), 79.5, 77.8, 77,7, 76.6, 75.1, 74.4, 74.4, 74.1, 73.2, 73.2, 60.6, 55.8, 16.7. Correlations between C1 of fucose and H6 and H6’ of the glucosamine unit were observed in gHMBC 2-D NMR spectrum confirming the fucose is linked to 6-O of the glucosamine. HRMS: m/z: calcd for C55H55NO11Na: [M+Na]+, 928.3673, found: 928.3654.

p-Tolyl 2-O-benzyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-1-thio-α-d-mannopyranoside (10α)

n-Bu2SnO (3.72 g, 14.6 mmol) was added to a solution of p-tolyl 4,6-O-benzylidene-1-thio-α-d-mannopyranoside[71] (4.9 g, 13.6 mmol) in toluene (65 mL) and the resulting mixture was refluxed using a Dean-Stark apparatus for 3 h. The reaction mixture was cooled to room temperature and p-methoxybenzyl chloride (2.8 mL, 20.4 mmol) and n-Bu4NI (1.01 g, 2.7 mmol) were added. The reaction mixture was refluxed again for 2 h followed by addition of H2O (2 mL) to quench the reaction. After removing the solvents, the residue was purified by column chromatography (silica gel, hexanes: EtOAc 7 : 3) to give p-tolyl 4,6-O-benzylidene-3-O-p-methoxybenzyl-1-thio-α-d-mannopyranoside (5.96 g, 92%). This product was dissolved in anhydrous DMF (50 mL) and NaH (95%, 457 mg, 18 mmol) was added to the mixture. After 1 h at room temperature, benzyl bromide (2.47g 18 mmol) was added to the mixture and stirred overnight. The reaction mixture was diluted with EtOAc (300 mL), washed with water, 10% of NH4Cl and brine and dried over anhydrous Na2SO4. The organic phase was evaporated and the residue was purified by flash column chromatography (silica gel, hexanes: EtOAc = 4 : 1) to give compound 10α (6.3 g, 90%). 1H NMR (600 MHz, CDCl3): δ = 7.58-7.53 (m, 2 H), 7.44-7.27 (m, 12 H), 7.15-7.11 (m, 2 H), 6.93-6.87 (m, 2 H), 5.67 (s, 1 H), 5.46 (d, 3J (H, H) = 1.8 Hz, 1 H), 4.76 (d, 3J (H, H) = 12 Hz, 1 H), 4.73 (s, 2 H), 4.62 (d, 3J (H, H) = 12 Hz, 1 H), 4.36-4.30 (m, 2 H), 4.27-4.22 (dd, 3J (H, H) = 10.8, 4.2 Hz, 1 H), 4.40-4.10 (m, 1 H), 4.10-3.97 (m, 1 H), 3.94- 3.88 (m, 1 H), 3.82 (s, 3 H), 2.35 (s, 3 H); 13C NMR (150 MHz, CDCl3): δ =159.5, 138.2, 138.1, 137.9, 132.6, 130.7, 130.2, 130.16, 129.6, 129.1, 128.7, 128.5, 128.4, 128.1, 126.4, 114.0, 101.7, 87.7, 79.3, 78.2, 76.0, 73.2, 73.0, 68.8, 65.8, 21.4. HRMS: m/z calcd for C35H36O6SNa, [M+Na]+, 607.2130, found 607.2089.

p-Tolyl 2-O-benzyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (12β)

A mixture of donor 10α (226 mg, 387 µmol) and TTBP (180 mg, 726 µmol) in dry CH2Cl2 (20 mL) was stirred with activated molecular sieves 4Å (800 mg) for 30 minutes at room temperature and then cooled to −75°C. AgOTf (118 mg, 0.46 mmol) in acetonitrile (300 µL) was added directly to the solution without touching the flask wall. After 10 minutes, orange colored p-TolSCl (55 µl, 387 µmol) was added via a microsyringe. Since the reaction temperature was lower than the freezing point of p-TolSCl, p-TolSCl was added directly into the reaction mixture to prevent it from freezing on the flask wall. The characteristic yellow color of p-TolSCl in the reaction solution dissipated rapidly within a few seconds indicating depletion of p-TolSCl. After the donor was completely consumed according to TLC analysis (about 5 minutes at −78 °C), a solution of acceptor 11 (345 mg, 579 µmol) in CH2Cl2 (6 mL) was added slowly along the flask wall. The reaction mixture was allowed to warm up to −20°C and quenched by using triethylamine. The reaction mixture was diluted with CH2Cl2 and filterer through Celite. The Celite was washed extensively with CH2Cl2 until TLC indicated no more organic compounds in the filtrate. The organic layer was then extracted with satd. NaHCO3 solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. After flash column chromatography (hexanes : EtOAc = 7 : 3), the α and β mixture (231 mg, 82% based on consumption donor, recover donor 70 mg) was obtained. The pure 12α (33 mg) and 12β (198 mg) (α:β = 1:6) were isolated by column chromatography using 3% acetone in toluene. [α]D20 = +19.4, (c = 1.0 in CHCl3). Data for 12β: 1H NMR (600 MHz, CDCl3): δ = 7.83-7.80 (m, 1H), 7.71-7.64 (m, 2H), 7.63-7.60 (m, 1H), 7.48-7.42 (m, 4H), 7.38-7.30 (m, 7H), 7.29-7.21 (m, 8H), 7.01-6.98 (m, 2H), 6.92-6.89 (m, 2H), 6.86-6.80 (m, 5H), 5.51 (s, 1H), 5.44 (d, 3J (H, H) = 10.2 Hz, 1 H), 4.90-4.82 (m, 3H), 4.65 (d, 3J (H, H) = 12 Hz, 1 H), 4.58 (d, 3J (H, H) = 12 Hz, 1 H), 4.55 (s, 1H), 4.51 (d, 3J (H, H) = 12 Hz, 1 H), 4.40 (t, 2H, J = 12.6 Hz), 4.25-4.22 (m, 1H), 4.19-4.15 (m, 2H), 4.05 (t, 1H, J = 9.6 Hz), 3.96 (t, 1H, J = 9.6 Hz), 3.78 (s, 3H), 3.75 (d, 3J (H, H)= 3 Hz, 1 H), 3.68 (d, 3J (H, H) = 12 Hz, 1 H), 3.59-3.51 (m, 3H), 3.43 (dd, 1H, J = 3.0, 10.2 Hz), 3.16-3.12 (m, 1H), 2.27 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 168.4, 167.5, 159.4, 138.9, 138.8, 138.5, 138.2, 137.9, 134.1, 134.1, 133.9, 133.7, 131.9, 131.8, 130.8, 129.8, 129.4, 129.3, 129.1, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.2, 126.3, 123.7, 123.5, 113.9, 102.3 (C1 mannose, 1J (C1, H1) = 154 Hz), 101.6, 83.4 (C1 glucosamine, 1J (C1, H1) = 157 Hz), 79.5, 79.4, 78.9, 78.2, 77.3, 75.2, 75.1, 73.8, 72.6, 68.9, 68.8, 67.6, 55.5, 55.0, 21.4; HRMS: m/z: calcd for C63H61NNaO12S [M+Na]+: 1078.3812, found: 1078.3807.

p-Tolyl 2,4-di-O-benzyl-4,6-di-O-levulinoyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (14)

A solution of compound 12β (210 mg, 0.20 mmol) in CH2Cl2 (6 mL) was stirred with activated molecular sieves (MS AW 300) (600 mg) and cooled to −78°C. Triethylsilane (130 µL, 0.20 mmol) was added followed by dichlorophenyl borane (105 µL, 0.20 mmol). The reaction was stirred for 6 h and quenched by adding triethyl amine. The reaction mass was diluted with CH2Cl2 and extracted with a saturated aqueous NaHCO3 solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Diol p-tolyl 2,4-di-O-benzyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (167 mg) was obtained from flash column chromatography (EtOAc: hexanes, 1: 1) in 89% yield. [α]D20 = + 40.6, (c = 1.0 in CHCl3). 1H NMR (600 MHz, CDCl3): δ = 7.83-7.80 (m, 1H), 7.71-7.61 (m, 3H), 7.40-7.25 (m, 16H), 7.04-7.01 (m, 2H), 6.92-6.88 (m, 5H), 5.43 (d, 3J (H, H) = 10.2 Hz, 1 H), 4.98 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.86 (d, 3J (H, H) = 12.6 Hz, 1 H), 4.81-4.79 (d, 3J (H, H) = 10.8 Hz, 1 H), 4.66-4.58 (m, 3H), 4.53 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.52-4.48 (d, 3J (H, H) = 12 Hz, 1 H), 4.25-4.17 (m, 2H), 3.99-3.96 (t, 3J (H, H) = 8.4 Hz, 1 H), 3.80-3.69 (m, 3H), 3.64-3.61 (m, 2H), 3.51-3.47 (m, 1H), 3.44-3.39 (m, 2H), 3.14-3.11 (m, 1H), 2.28 (s, 3H), 1.86-1.83 (m, 1H); 13C NMR (100 MHz, CDCl3): δ = 168.5, 167.9, 138.8, 138.6, 137.8, 137.5, 136.6, 136.2, 134.3, 134.2, 134.1, 133.9, 133.2, 132.1, 131.9, 131.6, 129.9, 128.8, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.3, 123.9, 123.5, 123.3, 96.8, 96.7, 78.776.3, 75.5, 74.7, 74.6, 74.4, 74.0, 73.6, 70.9, 69.9, 62.5, 60.7, 56.5, 56.1, 27.2; ESI-MS: m/z: calcd for C55H55NO11SNa: [M+Na]+, 960.35, found: 960.36. To a solution of p-tolyl 2,4-di-O-benzyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (167 mg, 0.178 mmol) in CH2Cl2 (5 mL), levulinic acid (73 µL, 0.712 mmol), N-ethyl N,N-dimethylaminopropyl carbodiimide hydrochloride (EDC) (136.5 mg, 0.712 mmol) and N,N-dimethylamino pyridine (4.4 mg, 0.036 mmol) were added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with CH2Cl2 (50 mL) and extracted with satd. NaHCO3 solution. The organic layer was evaporated to dryness and compound 14 (173 mg) was obtained in 86 % yield after flash column chromatographic purification (hexanes : EtOAc = 2:1). [α]D20 = +17.8, (c = 1.0 in CHCl3). 1H NMR (600 Hz, CDCl3): δ = 7.78-7.74 (m, 1 H), 7.68-7.62 (m, 2H), 7.64-7.61 (m, 1 H), 7.42-7.24 (m, 17 H), 6.99-6.97 (m, 1 H), 6.83-6.81 (m, 2 H), 6.73-6.69 (m, 3 H), 5.39 (d, 3J (H, H) = 10.2 Hz, 1 H), 4.85 (d, 3J (H, H) = 12 Hz, 1H), 4.80 (d, 3J (H, H) = 12 Hz, 1 H), 4.77 (dd, 3J (H, H) = 3.0, 9.6 Hz, 1 H), 4.70 (d, 3J (H, H) = 12 Hz, 1 H), 4.67 (s, 2 H), 4.54 (d, 3J (H, H) = 12 Hz, 1 H), 4.53 (d, 3J (H, H) = 12 Hz, 1 H), 4.42 (d, 3J (H, H) = 12.6 Hz, 1 H), 4.32 (dd, 3J (H, H) = 4.8, 12 Hz, 1 H), 4.24-4.10 (m, 4 H), 4.02 (t, 3J (H, H)= 9.6 Hz, 1 H), 3.92 (d, 3J (H, H) = 3.0 Hz, 1 H), 3.87 (t, 3J (H, H) = 9.6 Hz, 1 H), 3.77 (d, 3J (H, H) = 10.8 Hz, 1 H), 3.68 (dd, 3J (H, H) = 3.0, 12 Hz, 1 H), 3.55 (d, 3J (H, H) =.6 Hz, 1 H), 3.38-3.33 (m, 1 H), 2.67-2.33 (m, 8 H), 2.25 (s, 3 H), 2.12 (s, 3 H), 2.01 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ = 206.7, 206.2, 172.3, 172.0, 167.9, 167.2, 138.7, 138.6, 138.2, 137.89, 137.85, 133.8, 133.6, 129.5, 128.5, 128.4, 128.2, 127.94, 127.89, 127.78, 127.75, 127.71, 127.66, 127.51, 126.8, 123.3, 123.2, 100.7, 83.18, 79.0, 78.9, 77.9, 76.2, 76.1, 74.8, 74.7, 74.6, 73.4, 73.07, 73.05, 68.5, 63.1, 54.7, 37.74, 37.69, 29.8, 29.7, 27.88, 27.85, 21.1. MALDI-MS: m/z: calcd for C65H67NO15SNa: [M+Na]+, 1156.42, found: 1156.61.

Benzyl 2,4-di-O-benzyl-3,6-di-O-levulinoyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranosyl-(1→4)-(2,3,4-tri-O-benzyl-α-l-fucopyranosyl-(1→6))-3-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (15)

The mixture of donor 14 (100 mg, 88 µmol), acceptor 9 (64 mg, 70.4 µmol) and freshly activated MS 4Å (600 mg) in dry CH2Cl2 (6 mL) was stirred for 30 min at room temperature, and cooled down to −70°C followed by the addition of AgOTf (68 mg, 264 µmol) in anhydrous acetonitrile (0.1 mL) directly to the solution without touching the wall of reaction flask. After 5 min, p-TolSCl (12.8 µL, 88 µmol) was added via a microsyringe. The reaction mixture was stirred for 1.5 h until the temperature reached −20°C and triethylamine (30 µL) was added. The mixture was diluted with CH2Cl2 (50 mL) filtered through Celite. The filtrate was concentrated and purified by flash column chromatography (hexanes : EtOAc = 3 : 2) to give compound 15 (116 mg, 86%). [α]D20 = −28.0 (c = 1.0 in CHCl3). 1H NMR (600 Hz, CDCl3): δ = 7.85-7.81 (m, 1 H), 7.80-7.76 (m, 1 H), 7.72-7.60 (m, 4H), 7.59-7.56 (m, 1H), 7.52-7.40 (m, 6H), 7.36-7.20 (m, 18H), 7.17-7.12 (m, 3H), 7.05-7.02 (m, 3 H), 6.98-6.94 (m, 4 H), 6.92-6.88 (m, 2 H), 6.80-6.71 (m, 8 H), 5.52 (d, 1 H, J = 8.4 Hz), 4.92-4.70 (m, 10H), 4.68 (s, 1 H), 4.66-4.47 (m, 8 H), 4.39 (d, 3J (H, H) = 12.6 Hz, 1 H), 4.33 (d, 3J (H, H) = 12 Hz, 1 H), 4.30-4.10 (m, 8 H), 4.09-4.04 (m, 1 H), 3.95-3.92 (m, 3 H), 3.84-3.76 (m, 4 H), 3.68 (d, 3J (H, H) = 9.0 Hz, 1 H), 3.60-3.56 (m, 2 H), 3.37-3.30 (m, 2 H), 3.22 (d, 3J (H, H) = 9.6 Hz, 1 H), 2.62-2.27 (m, 8 H), 2.10 (s, 3 H), 1.93 (s, 3 H), 0.95 (d, 3J (H, H) = 5.4 Hz, 3 H). 13C NMR (150 Hz, CDCl3): δ = 206.9, 206.4, 172.5, 172.3, 168.4, 168.0, 167.94, 167.85, 139.3, 139.2, 139.1, 139.00, 138.86, 138.85, 138.2, 138.1, 137.3, 134.1, 133.9, 132.1, 131.9, 131.8, 128.9, 128.8, 128.68, 128.67, 128.6, 128.40, 128.35, 128.3, 128.13, 128.11, 128.08, 128.04, 128.00, 127.99, 127.9, 127.81, 127.77, 127.74, 127.71, 127.6, 127.50, 127.48, 127.2, 127.1, 123.7, 123.5, 100.8, 97.1, 96.92, 96.85, 79.8, 79.2, 77.9, 77.1, 76.9, 76.5, 76.2, 75.4, 75.3, 75.0, 74.96, 74.7, 74.6, 74.6, 73.9, 73.5, 73.46, 73.3, 73.28, 72.7, 70.1, 68.2, 66.2, 64.0, 63.3, 60.6, 56.8, 56.1, 38.0, 37.99, 30.0, 29.9, 28.2, 28.1, 16.6. HRMS: m/z: calcd for C113H114N2O26Na, [M+Na]+, 1938.7592, found: 1938.7534.

Benzyl 2,4-di-O-benzyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranosyl-(1→4)-(2,3,4-tri-O-benzyl-α-l-fucopyranosyl-(1→6))-3-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (6)

To a solution of 15 (300 mg, 0.157 mmol) in CH2Cl2/MeOH (1:1, 8 mL), hydrazine acetate (60 mg, 0.65 mmol) was added and stirred at room temperature for 90 min. The reaction mixture was diluted with CH2Cl2 (100 mL) and extracted with satd. NH4Cl solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The compound 6 (217 mg, 81%) was isolated by flash column chromatography (hexanes: EtOAc = 2 : 3). [α]D20 = −16.5 (c = 1.0 in CHCl3). 1H NMR (600 MHz, CDCl3): δ = 7.92-7.88 (m, 1 H), 7.84-7.78 (m, 1 H), 7.76-7.62 (m, 5 H), 7.58-7.55 (m, 1H), 7.52-7.42 (m, 1H), 7.40-7.22 (m, 22H), 7.08-7.00 (m, 7H), 6.98-6.90 (m 7H), 6.81-6.76 (m, 3H), 5.64 (d, 3J (H, H) = 8.4 Hz, 1 H), 5.00-4.90 (m, 7 H), 4.86-4.76 (m, 4 H), 4.67-4.60 (m, 5 H), 4.57-4.51 (m, 2 H), 4.46-4.26 (m, 6 H), 4.24-4.16 (m, 3 H), 4.10-4.00 (m, 3 H), 3.93 (d, 3J (H, H) = 10.2 Hz, 1 H), 3.86 (d, 3J (H, H) = 9.6 Hz, 1 H), 3.77 (d, 3J (H, H) = 10.2 Hz, 1 H), 3.75 (d, 3J (H, H) = 11.4 Hz, 1 H), 3.69-3.64 (m, 2 H), 3.60 (d, 3J (H, H) = 3.6 Hz, 1 H), 3.55-3.49 (m, 1 H), 3.45-3.40 (m, 3 H), 3.29 (d, 3J (H, H)= 9.6 Hz, 1 H), 3.18-3.13 (m, 1 H), 2.34 (d, 3J (H, H) = 9.0 Hz, 1 H), 1.02 (d, 3J (H, H) = 6.6 Hz, 3 H). 13C NMR (150 MHz, CDCl3): δ = 168.7, 168.1, 168.0, 167.9, 139.2, 139.1, 139.0, 138.9, 138.8, 138.5, 138.3, 1378.0, 137.3, 134.3, 134.1, 133.9, 132.1, 132.0, 131.7, 128.9, 128.74, 128.69, 128.66, 128.64, 128.61, 128.4, 128.38, 128.3, 128.26, 128.2, 128.1, 128.08, 128.0, 127.94, 127.81, 127.8, 127.77, 127.7, 127.64, 127.6, 127.4, 127.2, 123.9, 123.5, 101.4, 97.0, 96.99, 96.9, 79.8, 79.2, 79.0, 77.8, 77.4, 76.8, 76.2, 75.4, 75.37, 75.36, 75.3, 75.0, 74.9, 74.7, 74.67, 74.4, 73.7, 73.69, 73.4, 72.7, 70.2, 68.1, 66.3, 64.0, 62.6, 60.7, 56.7, 56.1, 16.6. HRMS: m/z: calcd for [M+Na]+, C103H102N2O22Na, 1742.6855, found: 1742.6771.

Benzyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-d-mannopyranosyl-(1→6)-(2-O-acetyl-3,4,6-tri-O-benzyl-α-d-mannopyranosyl-(1→3))-2,4-di-O-benzyl-β-d-mannopyranosyl-(1→4)-O-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranosyl-(1→4)-(2,3,4-tri-O-benzyl-α-l-fucopyranosyl-(1→6))-3-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (16)

The mixture of donor 5 (26 mg, 45 µmol), acceptor 6 (17 mg, 15.7 µmol) and freshly activated MS 4Å (600 mg) in anhydrous CH2Cl2 (6 mL) was stirred for 30 minutes at room temperature and cooled down to −78°C followed by the addition of AgOTf (34 mg, 133 µmol) in anhydrous acetonitrile (0.1 mL) directly to the solution without touching the wall of reaction flask. After 5 min, p-TolSCl (6.8 µL, 45 µmol) was added via a microsyringe. The reaction mixture was stirred for 1.5 h until the temperature reached 0°C, which was followed by addition of TMSOTf (2 µL). The reaction was stirred further for 1.5 h from 0°C to room temperature and triethylamine (25 µL) was added. The mixture was diluted with CH2Cl2 (50 mL) and filtered through Celite. The Celite was washed with CH2Cl2 until no organic product was present in the filtrate by TLC. The filtrate was combined, concentrated and purified by flash column chromatography (hexanes : EtOAc = 3 : 2) to give compound 16 (32 mg, 76%). [α]D20 = + 4.5 (c = 1.0 in CHCl3). 1H NMR (600 Hz, CDCl3): δ = 7.76-7.71 (m, 2 H), 7.69-7.58 (m, 4 H), 7.50-7.45 (m, 4 H), 7.41-7.16 (m, 42 H), 7.14-7.01 (m, 11 H), 6.99-6.93 (m, 4 H), 6.93-6.88 (m, 2 H), 6.78-6.68 (m, 6 H), 6.62-6.58 (m, 2 H), 5.49-5.46 (m, 2 H), 5.30-5.28 (m, 1 H), 5.14 (s, 1 H), 4.93 (d, 3J (H, H) = 8.4 Hz, 1 H), 4.92-4.80 (m, 10 H), 4.77 (d, 3J (H, H)= 10.8 Hz, 1 H), 4.71 (d, 3J (H, H)= 11.4 Hz, 1 H), 4.67 (d, 3J (H, H)= 11.4 Hz, 1 H), 4.64-4.52 (m, 9 H), 4.50-4.43 (m, 4 H), 4.42-4.33 (m, 5 H), 4.29 (d, 3J (H, H)= 12.6 Hz, 1 H), 4.28-4.12 (m, 6 H), 4.10-4.04 (m, 2 H), 3.99-3.87 (m, 6 H), 3.85-3.70 (m, 7 H), 3.67-3.56 (m, 7 H), 3.5-3.48 (m, 2 H), 3.32-3.28 (dd, 3J (H, H) = 3.0, 10.2 Hz, 1 H), 3.21 (d, 3J (H, H) = 9.6 Hz, 1 H), 3.17-3.13 (m, 1 H), 2.10 (s, 3 H), 1.80 (s, 3 H), 0.96 (d, 3J (H, H)= 6.6 Hz, 3 H). 13C NMR (150 Hz, CDCl3): δ = 170.4, 169.9, 168.8, 167.78, 139.2, 139.0, 138.9, 138.85, 138.6, 138.3, 138.2, 138.15, 137.8, 137.7, 137.3, 133.9, 133.7, 132.1, 131.9, 131.7, 128.9, 128.7, 128.61, 128.5, 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 127.4, 127.3, 127.1, 127.0, 123.7, 123.4, 102.0, 99.7, 99.6, 98.5, 97.1, 96.8, 81.5, 79.8, 79.5, 78.9, 78.4, 77.98, 77.9, 76.7, 76.4, 75.7, 75.3, 75.2, 75.19, 75.0, 74.9, 74.85, 74.8, 74.7, 74.69, 74.67, 74.6, 74.5, 74.4, 74.2, 74.0, 73.7, 73.6, 73.5, 73.46, 72.6, 72.5, 72.0, 71.6, 71.4, 70.1, 70.0, 69.0, 68.9, 68.34, 68.129, 66.7, 66.2, 65.3, 64.0, 56.8, 56.0, 24.9, 21.3, 21.2, 16.7. MALDI-MS: m/z: calcd for C161H162N2O34Na, [M+Na]+, 2690.10, found: 2690.49.

Benzyl 3,4,6-tri-O-benzyl-α-d-mannopyranosyl-(1→6)-(3,4,6-tri-O-benzyl-α-d-mannopyranosyl-(1→3))-2,4-di-O-benzyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranosyl-(1→4)-(2,3,4-tri-O-benzyl-α-l-fucopyranosyl-(1→6))-3-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside (4)

The solution of compound 16 (242 mg, 90.6 µmol) in methanol (5 mL) and CH2Cl2 (2 mL) was stirred with NaOMe (12 mg, 0.5 mmol) at room temperature for 3 h, which was then neutralized to pH 5-6 with acetic acid. After evaporating the solvent, the residue was purified by flash column chromatography (hexanes: EtOAc = 1 : 1) to give 4 (184 mg, 79%). [α]D20 = +4.0 (c = 1.0 in CHCl3). 1H NMR (600 Hz, CDCl3): δ = 7.77-7.83 (m, 2 H), 7.72-7.61 (m, 4 H), 7.56-7.47 (m, 4 H), 7.45-7.39 (m, 4 H), 7.36-7.10 (m, 53 H), 7.09-7.03 (m, 2 H), 7.02-6.97 (m, 4 H), 6.94-6.91 (m, 2 H), 6.80-6.73 (m, 6 H), 6.70-6.66 (m, 2 H), 5.52 (d, 1 H, J = 8.4 Hz), 5.19 (s, 1 H), 5.00-4.82 (m, 11 H), 4.79-4.73 (m, 2 H), 4.67-4.45 (m, 15 H), 4.45-4.37 (m, 3 H), 4.36-4.23 (m, 6 H), 4.21-4.10 (m, 4 H), 4.04-3.96 (m, 4 H), 3.92-3.50 (m, 20 H), 3.35 (dd, 3J (H, H) = 2.4, 10.8 Hz, 1 H), 3.28 (d, 3J (H, H)= 9.6 Hz, 1 H), 3.21 (d, 3J (H, H)= 9.6 Hz, 1 H), 2.38 (bs, 1 H), 2.07 (bs, 1 H), 0.99 (d, 3J (H, H) = 6.6 Hz, 3 H). 13C NMR (150 Hz, CDCl3): δ = 168.3, 168.0, 139.2, 139.2, 139.15, 139.1, 138.9, 138.8, 138.75, 138.6, 138.4, 138.3, 138.2, 138.16, 138.1, 137.3, 134.1, 133.8, 132.1, 131.7, 128.9, 128.73, 128.70, 128.69, 128.67, 128.6, 128.5, 128.48, 128.46, 128.4, 128.3, 128.2, 128.16, 128.1, 128.09, 128.07, 128.04, 128.02, 127.98, 127.95, 127.93, 127.89, 127.85, 127.8, 127.76, 127.74, 127.72, 127.67, 127.6, 127.57, 127.3, 127.1, 127.06, 123.7, 123.4, 101.8, 101.5, 100.1, 97.2, 97.1, 96.8, 81.9, 80.3, 80.0, 79.56, 79.3, 78.8, 77.9, 76.5, 75.8, 75.5, 75.3, 75.1, 75.07, 75.0, 74.8, 74.75, 74.7, 74.6, 74.5, 74.4, 74.3, 74.0, 73.7, 73.5, 73.47, 72.7, 72.3, 72.2, 71.8, 71.4, 70.1, 69.0, 68.9, 68.2, 67.9, 66.7, 66.2, 64.0, 56.8, 56.1, 16.7. HRMS: m/z: calcd for C157H158N2O32Na, [M+Na]+, 2607.0730, found: 2607.0669.

Methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-α-d-galacto-2-nonulopyranosonate-2-(N-phenyl)-trifluoroacetimidate (17)

To a solution of methyl (p-tolyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-d-glycero-d-galacto-2-nonulopyranosid)onate (1.8 g, 3 mmol)[67] in methanol (30 mL) was added methanesulfonic acid (1.95 mL, 30 mmol) at room temperature. After being stirred at 60°C for 24 h, the reaction mixture was neutralized with triethylamine and concentrated in vacuo. The residue was used for next reaction without further purification. Methyl trichloroacetate (3.57 mL, 30 mmol) and triethylamine (0.84 mL, 6 mmol) were added to a solution of the residue in methanol (30 mL) at 0°C. The reaction mixture was stirred at room temperature for 6 h and all volatile solvents were removed. The remaining residue was dissolved in pyridine (10 mL), to which acetic anhydride (2 mL) and a catalytic amount of DMAP were added at 0°C. After being stirred at room temperature overnight, the reaction mixture was diluted with ethyl acetate, washed with water, 1 M HCl, saturated aq. NaHCO3, and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc : hexanes = 2 : 3) to give methyl (p-tolyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-5-trichloroacetamido-D-glycero-D-galacto-2-nonulopyranosid)onate (1.40 g, 2 mmol, 67%). To a solution of this thioglycoside (1.4 g, 2 mmol) in acetone (20 mL) and water (1 mL) was added NBS (930 mg, 5.23 mmol).[72] After being stirred for 0.5 h at room temperature, the solution was concentrated. The residue was diluted with CH2Cl2 and washed with saturated aq. NaHCO3. The organic layer was dried over Na2SO4 and concentrated leading to methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-β-d-glycero-d-galacto-2-nonulopyranosonate. To a solution of methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-d-galacto-2-nonulopyranosonate in acetone was added K2CO3 (3 eq) and N-phenyl trifluoroacetimidoyl chloride[66] (10 eq). After stirred at room temperature for 3 h, the mixture was filtered and then concentrated. The residue was subject to chromatography on silica gel column (hexanes: EtOAc = 3 : 2, containing 0.5% of triethylamine) leading to imidate 17 (α : β= 1 : 2, 79%). α : β mixture 1H NMR (400 MHz, CDCl3): δ = 7.32-7.25 (m, 1.5 H), 7.15-7.08 (m, 1.5 H), 6.83-6.77 (m, 1.5 H), 6.76-6.61 (m, 3 H), 5.50-5.47 (m, 1 H, β), 5.46-5.40 (m, 1 H, β), 5.36-5.33 (m, 0.5 H, α), 5.33-5.28 (m, 0.5 H, α), 5.18-5.13 (m, 1 H, β), 4.91-4.84 (m, 0.5 H, α), 4.55-4.49 (m, 1 H, β), 4.46-4.41 (m, 1 H, β), 4.38-4.32 (m, 0.5 H, α), 4.29-4.23 (m, 0.5 H, α), 4.18-4.12 (m, 2 H, β), 4.10-3.97 (m, 1 H, α), 2.94-2.87 (dd, 3J (H, H) = 13.6, 4.8 Hz, β, H-3eq, 1 H), 2.83-2.77 (dd, 3J (H, H) = 4.8, 13.6 Hz, 3-Heq,α, 0.5 H), 2.38-2.30 (dd, 3J (H, H)= 10.8, 13.6 Hz, 3-Hax,α, 0.5 H), 2.26-2.18 (dd, 3J (H, H) = 11.6, 13.6 Hz, 3-Hax, β 1 H), 2.20 (s, 1.5 H, α), 2.19 (s, 3 H, β), 2.09, 2.05, 1.84, 1.62 (each 3 H, each s, OAc from β isomer), 2.04 (s, 3 H, from 2 OAc of α isomer), 1.98 (s, 1.5 H, α), 1.96 (1.5 H, α). HRMS: m/z calcd for C28H30Cl3F3N2O13Na, [M+Na]+, 787.0663, found 787.0626.

p-Tolyl (methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-α-d-galacto-2-nonulopyranosonate-(2→3))-4,6-O-benzylidene-1-thio-β-d-galactopyranoside (24)

A mixture of the donor 17 (514 mg, 0.67 mmol) and acceptor 18 (411 mg, 1.1 mmol) and MS 3Å in anhydrous CH2Cl2/CH3CN (1 : 1, 30 mL) was stirred at room temperature under N2 for 30 min and then cooled to −65°C. TMSOTf (0.2 eq) was added. After stirred at −65°C for 2 h, the mixture was warmed up to room temperature and quenched with triethylamine (50 µL). The resulting mixture was filtered and concentrated. The residue was chromatographed on a silica gel column to afford the desired coupling product 24 (346 mg, 68% based on acceptor consumed, recover acceptor 210 mg). [α]D20 = −11.2, (c = 1.0 in CHCl3). 1H NMR (600 MHz, CDCl3): δ = 7.61-7.57 (m, 2 H), 7.38-7.30 (m, 5 H), 7.07-7.04 (m, 2 H), 6.52 (d, 3J (H, H) = 9.6 Hz, 1 H), 5.43-5.39 (m, 1 H), 5.32 (s, 1 H), 5.27-5.24 (dd, 1 H, J = 1.8, 9.6 Hz), 5.11-5.05 (m, 1 H), 4.63 (d, 3J (H, H) = 9.6 Hz, 1 H), 4.32 (dd, 3J (H, H) = 1.2, 12 Hz, 1 H), 4.29-4.24 (m, 2 H), 4.22 (dd, 3J (H, H) = 1.8, 10.8 Hz, 1 H), 4.10-4.05 (m, 2H), 3.97 (d, 3J (H, H)= 3.0 Hz, 1 H), 3.82 (q, 3J (H, H) = 10.2 Hz, 1 H), 3.76 (dt, 3J (H, H) = 0.6, 9.6 Hz, 1 H), 3.58 (s, 3 H), 3.54 (s, 1 H), 2.72 (dd, 3J (H, H) = 4.2, 12.6 Hz, 1 H), 2.58 (d, 3J (H, H) = 1.8 Hz, 1 H), 2.32 (s, 3 H), 2.19 (s, 3 H), 2.18 (s, 3 H), 2.00 (s, 3 H), 1.98 (s, 3 H), 1.94 (dd, 3J (H, H) = 6.0, 12.6 Hz, 1 H). 13C NMR (150 MHz, CDCl3): δ = 170.9, 170.7, 170.5, 170.4, 168.4, 162.3, 138.2, 138.15, 134.42, 134.41, 129.81, 129.77, 129.2, 128.3, 127.4, 126.8, 101.1, 97.4, 92.3, 86.8, 76.4, 74.0, 71.9, 69.7, 69.5, 68.1, 67.6, 67.3, 66.0, 62.5, 53.3, 51.8, 38.7, 21.6, 21.5, 21.04, 21.01, 20.97. HRMS: m/z, calcd for C40H46Cl3NO17SNa, [M+Na]+, 972.1444, found: 972.1448. The sialyl α2→3 galactose linkage was confirmed by a HMBC correlation between C2 of the sialic acid and H3 of the galactose unit. Stereochemistry of the linkage was established using compound 30.

p-Tolyl (methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-α-d-galacto-2-nonulopyranosonate-(2→3))-2-O-benzoyl-4,6-O-benzylidene-1-thio-β-d-galactopyranoside (30)

The mixture of compound 24 (475 mg, 0.5 mmol), pyridine (2 mL) and benzoyl chloride (1 mL) was stirred overnight at room temperature. The mixture was then diluted with CH2Cl2 (100 mL) and washed with HCl (1 M), water and satd. sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. After flash column chromatography (EtOAc:CH2Cl2:hexanes = 3 : 3 : 4), compound 30 was obtained (501 mg, 95%). [α]D20= −15.0, (c = 1.0 in CHCl3). 1H NMR (600 MHz, CDCl3): δ = 8.16-8.12 (m, 2 H), 7.60-7.56 (m, 1H), 7.52-7.46 (m, 2 H), 7.45-7.42 (m, 2 H), 7.39-7.35 (m, 2 H), 7.35-7.30 (m, 3 H), 7.02-7.00 (m, 2 H), 6.58 (d, 3J (H, H) = 10.2 Hz, 1 H), 5.49-5.44 (m, 1 H), 5.33 (t, 3J (H, H) = 9.6 Hz, 1 H), 5.32 (s, 1 H), 5.18 (dd, 3J (H, H) = 1.8, 9.6 Hz, 1 H), 4.92-4.86 (m, 2 H), 4.56 (dd, 3J (H, H) = 3.6, 9.6 Hz, 1 H), 4.34 (d, 3J (H, H) = 11.4 Hz, 1 H), 4.30 (dd, 3J (H, H) = 2.4, 6.6 Hz, 1 H), 4.10-4.03 (m, 2 H), 4.02-3.96 (m, 2 H), 3.72 (q, 3J (H, H) = 10.2 Hz, 1 H), 3.62 (s, 1 H), 3.54 (s, 3 H), 2.58 (dd, 3J (H, H) = 4.8, 13.2 Hz, 1 H), 2.29 (s, 3 H), 2.18 (s, 3 H), 2.00 (s, 3 H), 1.89 (s, 3 H), 1.76 (s, 3 H), 1.64 (t, 3J (H, H) = 13.2 Hz, 1 H). 13C NMR (150 MHz, CDCl3): δ = 170.9, 170.6, 170.1, 168.8, 165.1, 162.3, 138.4, 138.0, 134.6, 133.3, 130.8, 130.7, 130.2, 129.7, 129.3, 129.2, 128.7, 128.3, 127.7, 126.8, 101.3, 96.9, 92.2, 85.5, 73.73, 73.68, 71.9, 69.7, 69.5, 68.5, 68.0, 67.9, 67.2, 62.7, 53.2, 51.5, 38.5, 21.7, 21.5, 21.01, 20.93, 20.6. HRMS: m/z: calcd for C47H50Cl3NO18SNa, [M+Na]+, 1076.1712, found: 1076.1676. Three-bond coupling between CO2Me and H3ax of sialic acid was determined to be 5.8 Hz indicating α sialyl linkage.

Benzyl (methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-α-d-galacto-2-nonulopyranosonate-(2→3))-2-O-benzoyl-4,6-O-benzylidene-β-d-galactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside-(1→2)-3,4,6-tri-O-benzyl-α-d-mannopyranosyl-(1→6)-((methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-α-d-galacto-2-nonulopyranosonate-(2→3))-2-O-benzoyl-4,6-O-benzylidene-β-d-galactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside-(1→2)-3,4,6-tri-O-benzyl-α-d-mannopyranosyl-(1→3))-2,4-di-O-benzyl-β-d-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranosyl-(1→4)-(2,3,4-tri-O-benzyl-α-l-fucopyranosyl-(1→6))-3-O-benzyl-2-deoxy-2-phthalimido-β-d-glucopyranoside 2

A mixture of donor 30 (53 mg, 0.05 mmol) and freshly activated molecular sieves 4Å (800 mg) in CH2Cl2 (6 mL) was stirred at room temperature for 30 minutes and then cooled to −78 °C, which was followed by the addition of AgOTf (38 mg, 0.15 mmol) dissolved in acetonitrile (0.1 mL) without touching the wall of the flask. After 5 minutes, orange colored p-TolSCl (7.6 µL, 0.05 mmol) was added through a microsyringe. Since the reaction temperature was lower than the freezing point of p-TolSCl, p-TolSCl was added directly into the reaction mixture to prevent it from freezing on the flask wall. The characteristic yellow color of p-TolSCl in the reaction solution dissipated rapidly within a few seconds indicating its depletion. After the donor was completely consumed according to TLC analysis (about 5 minutes at −78 °C), a solution of acceptor 31 (21 mg, 0.04 mmol) and TTBP (20 mg, 0.08 mmol) in CH2Cl2 (1 mL) was slowly added dropwise via a syringe. The reaction mixture was stirred for 1.5 h until the temperature reached 0 °C, then cooled to −78°C again. A solution of diol acceptor 4 (32 mg, 0.0125 mmol) in CH2Cl2 (1 mL) was added, followed by AgOTf (26 mg, 0.1 mmol) in acetonitrile (0.1 mL). After 5 minutes, p-TolSCl (6.1 µL, 0.04 mmol) was added and the reaction mixture was stirred for 1.5 h until the temperature reached 0 °C, at which point triethylamine (30 µL) was added to quench the reaction. The reaction mixture was diluted with CH2Cl2 (50 mL) and filtered through Celite. The Celite was washed extensively with CH2Cl2 until TLC showed no products in the filtrate. The filtrate was combined, concentrated and purified by flash column chromatography (hexanes : EtOAc = 2 : 3) to give compound 2 (42 mg, 64.5%). [α]D20 = −2.5 (c = 1.0 in CHCl3). 1H NMR (600 Hz, CDCl3): δ = 8.20-8.12 (m, 4 H), 7.82-7.76 (m, 3 H), 7.72-6.84 (m, 103 H), 6.84-6.79 (m, 4 H), 6.78-6.74 (m, 3 H), 6.70-6.66 (m, 1 H), 6.49-6.45 (m, 1 H), 6.44-6.34 (m, 4 H), 5.56-5.40 (m, 5 H), 5.34 (s, 1 H), 5.32 (s, 1 H), 5.34-5.31 (m, 1 H), 5.24-5.19 (m, 2 H), 4.96- 4.85 (m, 6 H), 4.83-4.65 (m, 10 H), 4.63-4.41 (m, 12 H), 4.37-4.29 (m, 5 H), 4.28-4.19 (m, 8 H), 4.17-3.98 (m, 23 H), 3.94-3.83 (m, 7 H), 3.81-3.72 (m, 5 H), 3.68 (s, 2 H), 3.66-3.57 (m, 7 H), 3.56 (s, 3 H), 3.54-3.48 (m, 5 H), 3.47 (s, 3 H), 3.45-3.37 (m, 4 H), 3.33-3.15 (m, 8 H), 3.13-3.05 (m, 2 H), 2.90 (d, 3J (H, H) = 10.2 Hz, 1 H), 2.86 (d, 3J (H, H) = 10.8 Hz, 1 H), 2.77 (dd, 3J (H, H) = 5.4, 10.8 Hz, 1 H), 2.68 (dd, 3J (H, H) = 4.2, 12.6 Hz, 1 H), 2.64-2.56 (m, 2 H), 2.20 (s, 3 H), 2.19 (s, 3 H), 1.97 (s, 6 H), 1.95 (s, 3 H), 1.94 (s, 3 H), 1.91 (s, 3 H), 1.90 (s, 3 H), 1.65-1.56 (m, 2 H), 0.93 (d, 3J (H, H) = 6.6 Hz, 3 H). 13C NMR (150 Hz, CDCl3): δ = 170.9, 170.6, 170.5, 170.4, 170.3, 168.68, 168.65, 168.5, 168.11, 168.05, 168.00, 164.98, 164.90, 162.3, 139.4, 139.3, 139.1, 139.04, 138.99, 138.90, 138.82, 138.6, 138.5, 138.3, 138.2, 137.9, 137.8, 137.3, 133.7, 133.6, 132.1, 132.0, 131.1, 130.3, 130.2, 130.0, 129.2, 129.1, 129.0, 128.9, 128.6, 128.5, 128.42, 128.41, 128.36, 128.33, 128.27, 128.24, 128.22, 128.17, 128.14, 128.07, 128.02, 127.90, 127.82, 127.79, 127.76, 127.66, 127.57, 127.54, 127.45, 127.34, 127.23, 127.17, 127.00, 126.97, 126.91, 126.61, 126.59, 126.52, 125.41, 123.31, 101.9, 101.5, 101.5, 101.0, 98.5, 97.7, 97.10, 97.08, 96.98, 96.96, 96.85, 95.7, 92.4, 92.1, 81.6, 81.4, 80.3, 79.3, 78.3, 78.0, 77.0, 76.2, 76.1, 75.5, 75.0, 74.9, 74.7, 74.4, 74.3, 74.1, 74.0, 73.8, 73.40, 73.35, 73.33, 73.24, 73.1, 72.8, 72.7, 72.54, 72.45, 72.1, 72.0, 70.9, 70.6, 70.3, 70.1, 69.7, 69.4, 68.8, 68.4, 68.3, 67.8, 67.6, 67.3, 66.7, 66.6, 66.1, 62.7, 62.6, 56.8, 56.2, 56.0, 53.3, 53.2, 51.6, 38.9, 38.9, 21.6, 20.9, 20.9, 20.82, 20.76, 16.7. MALDI-MS: Calcd for C279H280Cl6N6NaO80, [M+Na]+, 5232.61 (one of the highest isotope peaks), found: 5232.24.

p-Tolyl (methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-trichloroacetamido-d-glycero-α-d-galacto-2-nonulopyranosonate-(2→3))-2-O-benzoyl-4,6-O-benzylidene-β-d-galactopyranosonyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-d-glucopyranoside (3)

See procedure for compound 2. The one pot reaction for synthesis of compound 2 was terminated prior to addition of acceptor 4. Compound 3 was purified from the reaction mixture by flash column chromatography (hexanes : EtOAc : CH2Cl2 = 4 : 3 : 3) in 82% yield. 1H NMR (600 MHz, CDCl3): δ = 8.15-8.12 (m, 2 H), 7.87-7.84 (m, 1 H), 7.81-7.77 (m, 1 H), 7.70-7.66 (m, 2 H), 7.63-7.59 (m, 1 H), 7.51-7.47 (m, 2 H), 7.46-7.42 (m, 2 H), 7.36-7.28 (m, 6 H), 7.28-7.24 (m, 2 H), 7.20-7.16 (m, 2 H), 6.93-6.90 (m, 2 H), 6.58 (d, 3J (H, H) = 9.6 Hz, 1 H), 5.56-5.46 (m, 3 H), 5.30 (s, 1 H), 5.21 (dd, 3J (H, H) = 1.8, 9.6 Hz, 1 H), 4.92-4.85 (m, 1 H), 4.76 (d, 3J (H, H) = 7.8 Hz, 1 H), 4.53 (dd, 3J (H, H) = 3.6, 10.2 Hz, 1 H), 4.43-4.38 (m, 2 H), 4.30 (dd, 3J (H, H) = 2.4, 12.6 Hz, 1 H), 4.22-4.06 (m, 7H), 4.05-4.00 (m, 1 H), 3.81-3.74 (m, 1 H), 3.68-3.64 (m, 1 H), 3.63 (s, 1 H), 3.61-3.57 (m, 1 H), 3.52-3.45 (m, 5 H), 2.63 (dd, 3J (H, H) = 4.2, 12.6 Hz, 1 H), 2.22 (s, 3 H), 2.20 (s, 3 H), 2.00 (s, 3 H), 1.95 (s, 3 H), 1.91 (s, 3 H), 1.62 (t, 3J (H, H) = 12.6 Hz, 1 H). 13C NMR (150 MHz, CDCl3) δ = 171.0, 170.59, 170.55, 170.1, 168.7, 168.2, 168.0, 165.1, 162.3, 138.8, 138.2, 137.7, 134.24, 134.18, 133.6, 133.4, 132.1, 132.0, 130.2, 130.1, 129.7, 129.2, 128.8, 128.5, 128.41, 128.35, 127.68, 127.66, 126.6, 123.9, 123.5, 101.7, 101.0, 96.9, 92.1, 83.6, 82.1, 78.2, 73.1, 72.8, 72.3, 72.0, 71.2, 70.0, 68.7, 68.6, 67.7, 67.5, 67.3, 66.7, 62.9, 60.7, 55.4, 53.2, 51.6, 38.8, 21.7, 21.31, 21.30, 20.9, 20.8. HRMS: calcd for C68H69Cl3N2O24SNa, [M+Na]+,1457.2924, found: 1457.2908. The Gal β1→4 GlcN linkage was confirmed by a HMBC correlation between C1 of the galactose and H4 of the glucosamine unit.

5-Acetamido-3,5-dideoxy-d-glycero-α-d-galacto-2-nonulopyranosylonate-(2→3)-β-d-galactopyranosyl-(1→4)-2-amino-2-deoxy-β-d-glucopyranosyl-(1→2)-α-d-mannopyranosyl-(1→6)-(5-acetamido-3,5-dideoxy-d-glycero-α-d-galacto-2-nonulopyranosylonate-(2→3)-β-d-galactopyranosyl-(1→4)-2-amino-2-deoxy-β-d-glucopyranosyl-(1→2)-α-d-mannopyranosyl-(1→3))-β-d-mannopyranosyl-(1→4)-2-amino-2-deoxy-β-d-glucopyranosyl-(1→4)-(α-l-fucopyranosyl-(1→6))-2-amino-2-deoxy-d-glucopyranoside (1)

Lithium iodide (200 mg) was added to a solution of compound 2 (80 mg) in dry pyridine (7 mL). The reaction mixture was refluxed at 120°C for 8 h under nitrogen atmosphere. The dark yellow solution was then evaporated to dryness and co-evaporated with toluene to yield a dark yellow amorphous solid which was directly used for next reaction. A solution of the above solid in ethanol (5 mL) was treated with NH2-NH2·H2O (1 mL) at 85°C for 48 h. The reaction mixture was concentrated and co-evaporated with toluene then selective acetylated with Ac2O (0.3 mL), Et3N (0.3 mL) in methanol (3 mL) at room temperature overnight. The acetylated mixture was concentrated and passed through a short column of silica gel and eluted with CH2Cl2/MeOH to give compound 22. A mixture of 22, 10% Pd(OH)2/C (30 mg) in methanol (3 mL) and water (1 mL) was stirred for 24 h at room temperature under H2 atmosphere. The solid was filtered off and the solution was concentrated to give compound 1 (18 mg, 49%). [α]D20 = −4.2 (c = 1.0 in H2O). 1H NMR (600 Hz, CDCl3): α:β mixture at the reducing end fucose δ 4.97 (d, 3J (H, H) = 2.4 Hz, 0.5 H), 4.91 (s, 1 H), 4.72 (s, 1H), 4.70-4.68 (m, 1 H), 4.57-4.54 (m, 1 H), 4.47-4.44 (m, 1 H), 4.38-4.33 (m, 4 H), 4.08 (bs, 1 H), 4.02 (bs, 1 H), 3.94-3.88 (m, 4H), 3.80-3.28 (m, 68H), 2.58 (dd, 3J (H, H) = 3.6, 12.0 Hz, 2 H), 1.88-1.82 (m, 12 H), 1.62 (t, 3J (H, H) = 12.0 Hz, 2 H), 1.06-1.02 (m, 3 H). ESI-MS: (neg. mode) Calcd for C90H148N6O66 (M-2H)2−: 1183.42, found: 1183.83.

Supplementary Material

Supporting info

Supporting information for this article is available on the WWW under http://www.chemeurj.org/ or from the author.

graphic file with name nihms110814f5.jpg

Acknowledgements

This work was supported by the National Institute of General Medical Sciences (NIH, R01-GM72667) and a CAREER award from the National Science Foundation (CHE 0547504).

References

  • 1.Dwek RA. Chem. Rev. 1996;96:683–720. doi: 10.1021/cr940283b. [DOI] [PubMed] [Google Scholar]
  • 2.André S, Kožár T, Schuberth R, Unverzagt C, Kojima S, Gabius H-J. Biochemistry. 2007;46:6984–6995. doi: 10.1021/bi7000467. and references cited therein. [DOI] [PubMed] [Google Scholar]
  • 3.Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Nature. 2006;440:435–436. doi: 10.1038/440435a. [DOI] [PubMed] [Google Scholar]
  • 4.Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. J. Biol. Chem. 2003;278:3466–3473. doi: 10.1074/jbc.M210665200. [DOI] [PubMed] [Google Scholar]
  • 5. Compound 1 has been characterized within an N glycan mixture isolated from carbohydrates attached to human γ-Interferon. See: Mutsaers JHGM, Kamerling JP, Devos R, Guisez Y, Fiers W, Vilegenthart JFG. Eur. J. Biochem. 1986;156:651–654. doi: 10.1111/j.1432-1033.1986.tb09627.x.
  • 6.Johnson PJ, Poon TCW, Hjelm NM, Ho CS, Ho SKW, Welby C, Stevenson D, Patel T, Parekh R, Townsend RR. Brit. J. Can. 1999;81:1188–1195. doi: 10.1038/sj.bjc.6690828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Taketa K. Electrophoresis. 1998;19:2595–2602. doi: 10.1002/elps.1150191506. [DOI] [PubMed] [Google Scholar]
  • 8.Tajiri M, Ohyama C, Wada Y. Glycobiology. 2008;18:2–8. doi: 10.1093/glycob/cwm117. [DOI] [PubMed] [Google Scholar]
  • 9.Chen F-TA, Evangelista RA. Electrophoresis. 1998;19:2639–2644. doi: 10.1002/elps.1150191512. [DOI] [PubMed] [Google Scholar]
  • 10.Watson E, Bhide A, van Halbeek H. Glycobiology. 1994;4:227–237. doi: 10.1093/glycob/4.2.227. [DOI] [PubMed] [Google Scholar]
  • 11.Chen G, Wan Q, Tan Z, Kan C, Hua Z, Ranganathan K, Danishefsky SJ. Angew. Chem. Int. Ed. 2007;46:7383–7387. doi: 10.1002/anie.200702865. and references cited therein. [DOI] [PubMed] [Google Scholar]
  • 12.Unverzagt C, Eller S, Mezzato S, Schuberth R. Chem. Eur. J. 2008;14:1304–1311. doi: 10.1002/chem.200701251. and references cited therein. [DOI] [PubMed] [Google Scholar]
  • 13.Nakano J, Ishiwata A, Ohta H, Ito Y. Carbohydr. Res. 2007;342:675–695. doi: 10.1016/j.carres.2006.12.022. and references cited therein. [DOI] [PubMed] [Google Scholar]
  • 14.Jonke S, Liu K, Schmidt RR. Chem. Eur. J. 2006;12:1274–1290. doi: 10.1002/chem.200500707. [DOI] [PubMed] [Google Scholar]
  • 15.Rising TWDF, Claridge TDW, Davies N, Gamblin DP, Moir JWB, Fairbanks AJ. Carbohydr. Res. 2006;341:1574–1596. doi: 10.1016/j.carres.2006.03.007. [DOI] [PubMed] [Google Scholar]
  • 16.Li B, Zeng Y, Hauser S, Song H, Wang L. J. Am. Chem. Soc. 2005;127:9692–9693. doi: 10.1021/ja051715a. [DOI] [PubMed] [Google Scholar]
  • 17.Dudkin VY, Miller JS, Danishefsky SJ. J. Am. Chem. Soc. 2004;126:736–738. doi: 10.1021/ja037988s. [DOI] [PubMed] [Google Scholar]
  • 18.Watt GM, Boons GJ. Carbohydr. Res. 2004;339:181–193. doi: 10.1016/j.carres.2003.10.029. [DOI] [PubMed] [Google Scholar]
  • 19.Ratner DM, Swanson ER, Seeberger PH. Org. Lett. 2003;5:4717–4720. doi: 10.1021/ol035887t. [DOI] [PubMed] [Google Scholar]
  • 20.Dudkin VY, Crich D. Tetrahedron Lett. 2003;33:1787–1789. [Google Scholar]
  • 21. For a chemoenzymatic synthesis of compound 1, see: Unverzagt C, André S, Seifert J, Kojima S, Fink C, Srikrishna G, Freeze H, Kayser K, Gabius H-J. J. Med. Chem. 2002;45:478–491. doi: 10.1021/jm0110237.
  • 22.Seifert J, Lergenmüller M, Ito Y. Angew. Chem. Int. Ed. 2000;39:531–534. doi: 10.1002/(sici)1521-3773(20000204)39:3<531::aid-anie531>3.3.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 23.Düffels A, Ley SV. J. Chem. Soc., Perkin Trans. 1. 1999:375–378. [Google Scholar]
  • 24.Wu B, Hua Z, Warren D, Ranganathan K, Wan Q, Chen G, Tan Z, Chen J, Endoa A, Danishefsky SJ. Tetrahedron Lett. 2006;47:5577–5579. doi: 10.1016/j.tetlet.2006.09.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Garegg PJ. Adv. Carbohydr. Chem. Biochem. 1997;52:179–205. doi: 10.1016/s0065-2318(08)60091-8. [DOI] [PubMed] [Google Scholar]
  • 26.Teumelsan N, Huang X. J. Org. Chem. 2007;72:8976–8979. doi: 10.1021/jo7013824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Dan A, Lergenmüller M, Amano M, Nakahara Y, Ogawa T, Ito Y. Chem. Eur. J. 1998;4:2182–2190. [Google Scholar]
  • 28.Shao N, Guo Z. Pol. J. Chem. 2005;79:297–307. [Google Scholar]
  • 29.Gunther W, Kunz H. Angew. Chem. Int. Ed. 1990;29:1050. [Google Scholar]
  • 30.Attolino E, Rising TWDF, Heidecke CD, Fairbanks AJ. Tetrahedron Assym. 2007;18:1721–1734. [Google Scholar]
  • 31.Stork G, La Clair JJ. J. Am. Chem. Soc. 1996;118:247–248. [Google Scholar]
  • 32.Guo Z, Nakahara Y, Nakahara Y, Ogawa T. Bioorg. Med. Chem. 1997;5:1917–1924. doi: 10.1016/s0968-0896(97)00126-0. and references cited therein. [DOI] [PubMed] [Google Scholar]
  • 33.Crich D, Banerjee A, Yao Q. J. Am. Chem. Soc. 2004;126:14930–14934. doi: 10.1021/ja047194t. and references cited therein. [DOI] [PubMed] [Google Scholar]
  • 34.Crich D, Li H, Yao Q, Wink DJ, Sommer RD, Rheingold AL. J. Am. Chem. Soc. 2001;123:5826–5828. doi: 10.1021/ja015985e. [DOI] [PubMed] [Google Scholar]
  • 35.Crich D, Sun S. Tetrahedron. 1998;54:8321–8348. [Google Scholar]
  • 36.Crich D, Li W, Li H. J. Am. Chem. Soc. 2004;126:15081–15086. doi: 10.1021/ja0471931. [DOI] [PubMed] [Google Scholar]
  • 37.Ogawa T, Nakabayashi S. Carbohydr. Res. 1981;97:81–86. doi: 10.1016/s0008-6215(00)80764-8. [DOI] [PubMed] [Google Scholar]
  • 38.Regioselectivity of this glycosylation was confirmed by NMR analysis of compound 3, prepared from a separation reaction following the identical procedure.
  • 39.Miermont A, Zeng Y, Jing Y, Ye X-S, Huang X. J. Org. Chem. 2007;72:8958–8961. doi: 10.1021/jo701694k. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ellervik U, Magnusson G. J. Org. Chem. 1998;63:9314–9322. [Google Scholar]
  • 41.Zhang Z, Niikura K, Huang X, Wong C-H. Can. J. Chem. 2002;80:1051–1054. [Google Scholar]
  • 42.Vermeer HJ, Van Dijk CM, Kamerling JP, Vliegenthart JFG. Eur. J. Org. Chem. 2001:193–203. and references cited therein. [Google Scholar]
  • 43.Lemieux RU, Hendricks KB, Stick RV, James K. J. Am. Chem. Soc. 1975;97:4056–4062. [Google Scholar]
  • 44.Huang X, Huang L, Wang H, Ye X-S. Angew. Chem. Int. Ed. 2004;43:5221–5224. doi: 10.1002/anie.200460176. [DOI] [PubMed] [Google Scholar]
  • 45.Martichonok V, Whitesides GM. J. Org. Chem. 1996;61:1702–1706. doi: 10.1021/jo951711w. [DOI] [PubMed] [Google Scholar]
  • 46.Huang L, Wang Z, Li X, Ye X-S, Huang X. Carbohydr. Res. 2006;341:1669–1679. doi: 10.1016/j.carres.2006.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Bock K, Pedersen C. J. Chem. Soc., Perkin Trans. 2. 1974:293–297. [Google Scholar]
  • 48.Sakagami M, Hamana H. Tetrahedron Lett. 2000;41:5547–5551. [Google Scholar]
  • 49.Dudkin VY, Miller JS, Danishefsky SJ. Tetrahedron Lett. 2003;44:1791–1793. [Google Scholar]
  • 50.Wang W, Kong F. Angew. Chem. Int. Ed. 1999;38:1247–1250. doi: 10.1002/(SICI)1521-3773(19990503)38:9<1247::AID-ANIE1247>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 51.Boons GJ, Demchenko A. Chem. Rev. 2000;100:4539–4565. doi: 10.1021/cr990313g. [DOI] [PubMed] [Google Scholar]
  • 52.Tanaka H, Adachi M, Takahashi T. Chem. Eur. J. 2005;11:849–862. doi: 10.1002/chem.200400840. [DOI] [PubMed] [Google Scholar]
  • 53.Ando H, Koike Y, Koizumi S, Ishida H, Kiso M. Angew. Chem. Int. Ed. 2005;44:6759–6763. doi: 10.1002/anie.200501608. [DOI] [PubMed] [Google Scholar]
  • 54.Xia J, Alderfer JL, Piskorz CF, Matta KL. Chem. Eur. J. 2000;6:3442–3451. doi: 10.1002/1521-3765(20000915)6:18<3442::aid-chem3442>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 55.De Meo C, Demchenko A, Boons GJ. J. Org. Chem. 2001;66:5490–5497. doi: 10.1021/jo010345f. [DOI] [PubMed] [Google Scholar]
  • 56.Crich D, Li W. Org. Lett. 2006;8:959–962. doi: 10.1021/ol060030s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Yu C-S, Niikura K, Lin C-C, Wong C-H. Angew. Chem. Int. Ed. 2001;40:2900–2903. doi: 10.1002/1521-3773(20010803)40:15<2900::AID-ANIE2900>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  • 58.Tanaka K, Goi T, Fukase K. Synlett. 2003:2958–2962. [Google Scholar]
  • 59.Crich D, Wu B. Tetrahedron. 2008;64:2042–2047. doi: 10.1016/j.tet.2007.12.026. and references cited therein. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Farris MD, De Meo C. Tetrahedron Lett. 2007;48:1225–1227. [Google Scholar]
  • 61.Tanaka H, Nishiura Y, Takahashi T. J. Am. Chem. Soc. 2006;128:7124–7125. doi: 10.1021/ja0613613. [DOI] [PubMed] [Google Scholar]
  • 62.Donohoe TJ, Logan JG, Laffan DDP. Org. Lett. 2003;5:4995–4998. doi: 10.1021/ol0359620. [DOI] [PubMed] [Google Scholar]
  • 63.Sherman AA, Yudina ON, Mironov YV, Sukhova EV, Shashkov AS, Menshov VM, Nifantieva NE. Carbohydr. Res. 2001;336:13–46. doi: 10.1016/s0008-6215(01)00213-0. [DOI] [PubMed] [Google Scholar]
  • 64.Bélot F, Jacquinet J-C. Carbohydr. Res. 2000;325:93–106. doi: 10.1016/s0008-6215(99)00322-5. [DOI] [PubMed] [Google Scholar]
  • 65.Hanashima S, Castagner B, Esposito D, Nokami T, Seeberger PH. Org. Lett. 2007;9:1777–1779. doi: 10.1021/ol0704946. [DOI] [PubMed] [Google Scholar]
  • 66.Cai S, Yu B. Org. Lett. 2003;5:3827–3830. doi: 10.1021/ol0353161. [DOI] [PubMed] [Google Scholar]
  • 67.Ye X-S, Huang X, Wong C-H. Chem. Commun. 2001:974–975. [Google Scholar]
  • 68.Huang L, Huang X. Chem. Eur. J. 2007;13:529–540. doi: 10.1002/chem.200601090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Wang Z, Zhou L, El-boubbou K, Ye X-S, Huang X. J. Org. Chem. 2007;72:6409–6420. doi: 10.1021/jo070585g. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Nicolaou KC, Hummel CW, Iwabuchi Y. J. Am. Chem. Soc. 1992;114:3126–3128. [Google Scholar]
  • 71.Cumpstey I, Chayajarus K, Fairbanks AJ, Redgrave AJ, Seward CMP. Tetrahedron: Assym. 2004;15:3207–3221. [Google Scholar]
  • 72.Lin C-C, Huang K-T, Lin C-C. Org. Lett. 2005;7:4169–4172. doi: 10.1021/ol0515210. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting info

Supporting information for this article is available on the WWW under http://www.chemeurj.org/ or from the author.

RESOURCES